Emcure to launch generic breast cancer medicine
Posted by
www.biotecnika.org
Eribulin, sold by Japanese drug maker Eisai under brand name Halaven,
is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/emcure-to-launch-generic-breast-cancer-medicine/articleshow/68712323.cms
Subscribe to:
Post Comments (Atom)
Post a Comment